We extracted data regarding the following items: first author, publication year, study design, geographical location, study population (cutaneous psoriasis, PsA, or both), sample size, patient characteristics (age, sex, and body mass index), characteristics of psoriatic disease (disease duration and the usage of potential drugs that may affect bone formation), BMD measurements (device, site, and outcomes), and reported outcomes of osteoporosis and fractures. Systemic corticosteroids, methotrexate, and anti-tumor necrosis factor (TNF)-α agents were considered potential drugs that could be related to bone quality and fragility [27,28,29]. The conflict of interest study was also listed for each study. The primary endpoint was the absolute value of BMD. The secondary endpoints included effect estimates regarding osteoporosis and fractures.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.